Skip to main content
Scroll back to top

Bone-specific Alkaline Phosphatase (BAP)

Test Number 513002
Test number copied
CPT

84080
Synonyms
  • BAP
  • Ostase®
  • Skeletal Alkaline Phosphatase (SALP)
  • Share
  • Print
  • Updated on 04/14/2026

Test Details

Methodology

Immunochemiluminometric assay (ICMA)

Result Turnaround Time

3 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

Quantitative measurement of skeletal alkaline phosphatase to be used as an aid in the management of patients with Paget disease and osteoporosis

Limitations

Serum specimens with significant elevations of liver alkaline phosphatase may cause aberrantly elevated results with the Ostase® assay.

Contraindications

Patients who have undergone therapy that includes infusion with mouse monoclonal antibody may produce erroneous results.

Specimen Requirements

Specimen

Serum

Volume

1 mL

Minimum Volume

0.5 mL

Container

Gel-barrier tube or transport tube

Collection Instructions

Separate serum from cells within 45 minutes of collection. If a red-top tube is used, transfer separated serum to a plastic transport tube.

Stability Requirements

TemperaturePeriod
Room temperature14 days
Refrigerated14 days
Frozen14 days
Freeze/thaw cyclesStable x3

Reference Range

Reference interval change (November 2015)1-3

 

AgeMale (μg/L)Female (μg/L)
0 to 5 mNot establishedNot established
6 to 11 m48.2−170.250.4−154.0
1 y41.9−229.644.2−178.3
2 y41.7−139.434.9−195.4
3 to 4 y37.2−127.737.4−96.8
5 to 6 y42.0−104.231.4−100.8
7 to 8 y59.0−101.344.0−135.8
9 to 10 y50.4−133.047.9−150.8
11 to 12 y53.3−156.824.2−133.3
13 to 14 y77.5−169.819.8−92.7
15 to 16 y26.8−173.411.2−30.2
17 to 18 y15.4−69.88.8−29.0
19 to 20 y12.2−36.67.7−16.8
21 to 29 y7.4−27.7See below
30 to 34 y7.0−27.4See below
35 to 39 y4.0−27.0See below
40 to 44 y7.4−26.7See below
45 to 49 y7.5−26.4See below
50 to 54 y7.5−26.1See below
55 to 59 y7.5−25.7See below
60 to 64 y7.5−25.4See below
65 to 69 y7.6−25.1See below
70 to 74 y7.6−24.8See below
75 to 100 y7.6−24.4See below
Female
Premenopausal: 6.0−22.7 μg/L
Postmenopausal: 8.1−31.6 μg/L

Reference interval change (November 2015)1-3

Age

Male (μg/L)

Female (μg/L)

0 to 5 m

Not established

Not established

6 to 11 m

48.2−170.2

50.4−154.0

1 y

41.9−229.6

44.2−178.3

2 y

41.7−139.4

34.9−195.4

3 to 4 y

37.2−127.7

37.4−96.8

5 to 6 y

42.0−104.2

31.4−100.8

7 to 8 y

59.0−101.3

44.0−135.8

9 to 10 y

50.4−133.0

47.9−150.8

11 to 12 y

53.3−156.8

24.2−133.3

13 to 14 y

77.5−169.8

19.8−92.7

15 to 16 y

26.8−173.4

11.2−30.2

17 to 18 y

15.4−69.8

8.8−29.0

19 to 20 y

12.2−36.6

7.7−16.8

21 to 29 y

7.4−27.7

See below

30 to 34 y

7.0−27.4

See below

35 to 39 y

4.0−27.0

See below

40 to 44 y

7.4−26.7

See below

45 to 49 y

7.5−26.4

See below

50 to 54 y

7.5−26.1

See below

55 to 59 y

7.5−25.7

See below

60 to 64 y

7.5−25.4

See below

65 to 69 y

7.6−25.1

See below

70 to 74 y

7.6−24.8

See below

75 to 100 y

7.6−24.4

See below

Female

Premenopausal: 6.0−22.7 μg/L

Postmenopausal: 8.1−31.6 μg/L

Reference interval change (November 2015)1-3

 

Age Male (μg/L) Female (μg/L)
0 to 5 m Not established Not established
6 to 11 m 48.2−170.2 50.4−154.0
1 y 41.9−229.6 44.2−178.3
2 y 41.7−139.4 34.9−195.4
3 to 4 y 37.2−127.7 37.4−96.8
5 to 6 y 42.0−104.2 31.4−100.8
7 to 8 y 59.0−101.3 44.0−135.8
9 to 10 y 50.4−133.0 47.9−150.8
11 to 12 y 53.3−156.8 24.2−133.3
13 to 14 y 77.5−169.8 19.8−92.7
15 to 16 y 26.8−173.4 11.2−30.2
17 to 18 y 15.4−69.8 8.8−29.0
19 to 20 y 12.2−36.6 7.7−16.8
21 to 29 y 7.4−27.7 See below
30 to 34 y 7.0−27.4 See below
35 to 39 y 4.0−27.0 See below
40 to 44 y 7.4−26.7 See below
45 to 49 y 7.5−26.4 See below
50 to 54 y 7.5−26.1 See below
55 to 59 y 7.5−25.7 See below
60 to 64 y 7.5−25.4 See below
65 to 69 y 7.6−25.1 See below
70 to 74 y 7.6−24.8 See below
75 to 100 y 7.6−24.4 See below
Female
Premenopausal: 6.0−22.7 μg/L
Postmenopausal: 8.1−31.6 μg/L

Storage Instructions

Maintain specimen at room temperature.

Causes for Rejection

Gross lipemia

References

Delmas PD. Biochemical markers of bone turnover: Methodology and clinical use in osteoporosis. Am J Med. 1991 Nov 25;91(5B):59S-63S.1750421
Gualco G, Lava SAG, Garzoni L, et al. Transient benign hyperphophatasemia. J Pediatr Gastroenterol Nutr. 2013 Aug;57(2):167-171.23539049
van Straalen JP, Sanders E, Prummel MF, et al. Bone-alkaline phosphatase as indicator of bone formation. Clin Chim Acta. 1991 Sep 14;201(1-2):27-33.1790624

Footnotes

1. Wyness SP, Roberts WL, Straseski JA. Pediatric reference intervals for four serum bone markers using two automated immunoassays. Clin Chim Acta. 2013 Jan 16;415:169-172.23122966
2. Cavalier E, Delanaye P. Analytical performance of a new bone-specific ALP automated immunoassay. J Am Soc Nephrol 24. 2013:754A.
3. Michelsen J, Wallaschofski H, Friedrich N, et al. Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone. 2013 Dec;57(2):399-404.24076251

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
513002 Alk Phosphatase, Bone Specific 513004 Alk Phosphatase, Bone Specific ug/L 17838-4
513002 Alk Phosphatase, Bone Specific 511958 PDF 80563-0
Order Code513002
Order Code NameAlk Phosphatase, Bone Specific
Order Loinc
Result Code513004
Result Code NameAlk Phosphatase, Bone Specific
UofMug/L
Result LOINC17838-4
Order Code513002
Order Code NameAlk Phosphatase, Bone Specific
Order Loinc
Result Code511958
Result Code NamePDF
UofM
Result LOINC80563-0